Cargando…
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
INTRODUCTION: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Regenerative Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970134/ https://www.ncbi.nlm.nih.gov/pubmed/31988999 http://dx.doi.org/10.1016/j.reth.2019.10.004 |
_version_ | 1783489453965180928 |
---|---|
author | Fujita, Yasutaka Nishimura, Masuhiro Komori, Natsuki Watanabe Wada, Tamaki Shirakawa, Chikage Takenawa, Taichi Sawamoto, Osamu Doi, Masako |
author_facet | Fujita, Yasutaka Nishimura, Masuhiro Komori, Natsuki Watanabe Wada, Tamaki Shirakawa, Chikage Takenawa, Taichi Sawamoto, Osamu Doi, Masako |
author_sort | Fujita, Yasutaka |
collection | PubMed |
description | INTRODUCTION: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. METHODS: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. RESULTS: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. DISCUSSION: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use. |
format | Online Article Text |
id | pubmed-6970134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Japanese Society for Regenerative Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-69701342020-01-27 A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells Fujita, Yasutaka Nishimura, Masuhiro Komori, Natsuki Watanabe Wada, Tamaki Shirakawa, Chikage Takenawa, Taichi Sawamoto, Osamu Doi, Masako Regen Ther Original Article INTRODUCTION: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. METHODS: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. RESULTS: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. DISCUSSION: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use. Japanese Society for Regenerative Medicine 2020-01-16 /pmc/articles/PMC6970134/ /pubmed/31988999 http://dx.doi.org/10.1016/j.reth.2019.10.004 Text en © 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Fujita, Yasutaka Nishimura, Masuhiro Komori, Natsuki Watanabe Wada, Tamaki Shirakawa, Chikage Takenawa, Taichi Sawamoto, Osamu Doi, Masako A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title | A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_full | A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_fullStr | A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_full_unstemmed | A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_short | A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
title_sort | pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970134/ https://www.ncbi.nlm.nih.gov/pubmed/31988999 http://dx.doi.org/10.1016/j.reth.2019.10.004 |
work_keys_str_mv | AT fujitayasutaka apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT nishimuramasuhiro apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT komorinatsukiwatanabe apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT wadatamaki apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT shirakawachikage apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT takenawataichi apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT sawamotoosamu apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT doimasako apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT fujitayasutaka pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT nishimuramasuhiro pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT komorinatsukiwatanabe pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT wadatamaki pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT shirakawachikage pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT takenawataichi pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT sawamotoosamu pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells AT doimasako pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells |